{
    "name": "margetuximab",
    "comment": "Rx",
    "other_names": [
        "Margenza",
        "margetuximab-cmkb"
    ],
    "classes": [
        "Antineoplastics",
        "Anti-HER2"
    ],
    "source": "https://reference.medscape.com/drug/margenza-margetuximab-4000067",
    "pregnancy": {
        "common": [
            "Based on findings in animals and mechanism of action, fetal harm may occur when administered to pregnant females",
            "No data available on use in pregnant females to inform of the drug-associated risks",
            "In postmarketing reports, use of a HER2- directed antibody during pregnancy resulted in cases of oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death",
            "Verify pregnancy status of females of reproductive potential before initiation"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "IV administration to pregnant cynomolgus monkeys once every 3 weeks, starting at gestational day 20 until delivery, resulted in oligohydramnios and delayed infant kidney development",
                    "Animal exposures were â‰¥3x the human exposures at the recommended dose, based on peak plasma levels",
                    "Advise patients of potential risks to a fetus"
                ]
            },
            {
                "type": "Fetal/neonatal adverse reactions",
                "description": [
                    "Monitor treated females during pregnancy or within 4 months before conception for oligohydramnios",
                    "If oligohydramnios occurs, perform fetal testing appropriate for gestational age and consistent with community standards of care"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Females of reproductive potential: Use effective contraception during treatment and for 4 months following final dose "
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Lactation"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                " "
            ],
            "specific": [
                {
                    "type": "Left ventricular dysfunction",
                    "description": [
                        "May lead to reductions in LVEF",
                        "Evaluate cardiac function before and during treatment",
                        "Discontinue treatment for confirmed clinically significant decrease in left ventricular function"
                    ]
                },
                {
                    "type": "Embryofetal toxicity",
                    "description": [
                        "Exposure during pregnancy can cause embryofetal harm",
                        "Advise patients of risk and use for effective contraception"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "May cause fetal harm when administered to pregnant females",
                " "
            ],
            "specific": [
                {
                    "type": "Left ventricular dysfunction",
                    "description": [
                        "Left ventricular dysfunction may occur",
                        "Not studied in patients with pretreatment LVEF <50%, history of myocardial infarction or unstable angina within 6 months, or congestive heart failure NYHA class II-IV",
                        "Conduct thorough cardiac assessment (eg, history, physical examination, determination of LVEF by ECG or multiple gated acquisition (MUGA) scan",
                        "Measure baseline LVEF within 4 weeks before initiation; then every 3 months during and upon completion",
                        "Repeat LVEF at 4-week intervals if therapy withheld for significant left ventricular dysfunction"
                    ]
                },
                {
                    "type": "Infusion-related reactions",
                    "description": [
                        "Infusion-related reactions (IRRs) reported",
                        "Symptoms may include fever, chills, arthralgia, cough, dizziness, fatigue, nausea, vomiting, headache, diaphoresis, tachycardia, hypotension, pruritus, rash, urticaria, and dyspnea",
                        "Monitor for IRRs during administration and as clinically indicated after completing infusion",
                        "Have medications and emergency equipment available to immediately to treat IRRs "
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Anthracyclines",
                        "Avoid anthracycline-based therapy for up to 4 months after discontinuing margetuximab ",
                        "Patients treated with anthracyclines <4 months after discontinuing therapy may be at increased risk of cardiac dysfunction ",
                        "Interaction has not been studied with margetuximab ",
                        "Clinical data from other HER2-directed antibodies warrant consideration ",
                        "If use is unavoidable, closely monitor cardiac function"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Increased creatinine",
            "percent": "68"
        },
        {
            "name": "Fatigue",
            "percent": "57"
        },
        {
            "name": "asthenia",
            "percent": "52"
        },
        {
            "name": "Decreased hemoglobin",
            "percent": "40"
        },
        {
            "name": "Decreased leukocytes",
            "percent": "34"
        },
        {
            "name": "Decreased neutrophils",
            "percent": "33"
        },
        {
            "name": "Nausea",
            "percent": "32"
        },
        {
            "name": "Increased activated partial thromboplastin time",
            "percent": "32"
        },
        {
            "name": "aPTT",
            "percent": "31"
        },
        {
            "name": "Increased ALT",
            "percent": "30"
        },
        {
            "name": "Decreased lymphocytes",
            "percent": "25"
        },
        {
            "name": "Increased lipase",
            "percent": "24"
        },
        {
            "name": "Diarrhea",
            "percent": "23"
        },
        {
            "name": "Increased INR",
            "percent": "21"
        },
        {
            "name": "Increased AST",
            "percent": "21"
        },
        {
            "name": "Vomiting",
            "percent": "19"
        },
        {
            "name": "Increased alkaline phosphatase",
            "percent": "19"
        },
        {
            "name": "Pyrexia",
            "percent": "19"
        },
        {
            "name": "Constipation",
            "percent": "18"
        },
        {
            "name": "Headache",
            "percent": "17"
        },
        {
            "name": "Alopecia",
            "percent": "16"
        },
        {
            "name": "Abdominal pain",
            "percent": "14"
        },
        {
            "name": "Peripheral neuropathy",
            "percent": "14"
        },
        {
            "name": "Cough",
            "percent": "14"
        },
        {
            "name": "Decreased appetite",
            "percent": "13"
        },
        {
            "name": "Arthralgia",
            "percent": "13"
        },
        {
            "name": "myalgia",
            "percent": "13"
        },
        {
            "name": "Palmoplantar erythrodysesthesia",
            "percent": "11"
        },
        {
            "name": "Dyspnea",
            "percent": "10"
        },
        {
            "name": "Infusion",
            "percent": "10"
        },
        {
            "name": "related reaction",
            "percent": "6"
        },
        {
            "name": "Extremity pain",
            "percent": "6"
        },
        {
            "name": "Dizziness",
            "percent": "6"
        },
        {
            "name": "Stomatitis",
            "percent": "6"
        },
        {
            "name": "Decreased weight",
            "percent": "5"
        },
        {
            "name": "Dysgeusia",
            "percent": "1.5"
        },
        {
            "name": "Rash",
            "percent": "9"
        },
        {
            "name": "Insomnia",
            "percent": "7"
        },
        {
            "name": "Hypertension",
            "percent": "6"
        },
        {
            "name": "Syncope",
            "percent": "5"
        },
        {
            "name": "Decreased neutrophils",
            "percent": "4.4"
        },
        {
            "name": "Fatigue",
            "percent": "3.4"
        },
        {
            "name": "Increased lipase",
            "percent": "3.2"
        },
        {
            "name": "Decreased leukocytes",
            "percent": "2.3"
        },
        {
            "name": "Decreased lymphocytes",
            "percent": "2"
        },
        {
            "name": "Increased aPTT",
            "percent": "2"
        },
        {
            "name": "Decreased hemoglobin",
            "percent": "1.5"
        },
        {
            "name": "Diarrhea",
            "percent": "1.5"
        },
        {
            "name": "Increased ALT",
            "percent": "1.2"
        },
        {
            "name": "Increased AST",
            "percent": "1.1"
        },
        {
            "name": "Abdominal pain",
            "percent": "1.1"
        },
        {
            "name": "Infusion",
            "percent": "1.1"
        },
        {
            "name": "related reaction",
            "percent": "0.8"
        },
        {
            "name": "Increased INR",
            "percent": "0.8"
        },
        {
            "name": "Nausea",
            "percent": "0.8"
        },
        {
            "name": "Peripheral neuropathy",
            "percent": "0.4"
        },
        {
            "name": "Dyspnea",
            "percent": "0.4"
        },
        {
            "name": "Vomiting",
            "percent": "0.4"
        },
        {
            "name": "Constipation",
            "percent": "0.4"
        },
        {
            "name": "Extremity pain",
            "percent": "0.4"
        },
        {
            "name": "Pyrexia",
            "percent": null
        },
        {
            "name": "Cough",
            "percent": null
        },
        {
            "name": "Decreased appetite",
            "percent": null
        },
        {
            "name": "Arthralgia",
            "percent": null
        },
        {
            "name": "myalgia",
            "percent": null
        },
        {
            "name": "Increased creatinine",
            "percent": null
        }
    ]
}